Complications of myeloma and its treatments

Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Engels EA et al. Bone Marrow Transplant. 2014 Sep 29. doi: 10.1038/bmt.2014.213. [Epub ahead of print]. Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study. Kashyap R et al. Asia Pac J Clin Oncol. 2014 Sep 22.…

Current treatments

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. Benboubker L et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Moreau P et al. Br J Haematol. 2014 Sep 19. doi: 10.1111/bjh.13128. [Epub ahead of print]. Bortezomib, thalidomide and…

Related conditions

Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Higo H et al. Intern Med. 2014;53(16):1809-12. Epub 2014 Aug 15. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Kourelis TV et al. Am J Hematol. 2014 Aug 11. doi: 10.1002/ajh.23827. [Epub ahead of print]. Immunophenotypic analysis of…

General

Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. Hultcrantz M et al. Cancer Med. 2014 Aug 26. doi: 10.1002/cam4.316. [Epub ahead of print]. Bortezomib in multiple myeloma: systematic review and clinical considerations. Kouroukis TC et al. Curr Oncol. 2014 Aug;21(4):e573-603. doi: 10.3747/co.21.1798. Novel Agents In Cns Myeloma Treatment.…

Emerging treatments

Oral therapy for multiple myeloma: ixazomib arriving soon.Moreau P. Blood. 2014 Aug 14;124(7):986-7. doi: 10.1182/blood-2014-06-581611.A multicenter, open-label phase II study of recombinant CPT (circularly permuted TRAIL) plus thalidomide in patients with relapsed and/or refractory multiple myeloma.Geng C et al. Am J Hematol. 2014 Aug 4. doi: 10.1002/ajh.23822. [Epub ahead of print].Novel AKT inhibitor afuresertib shows…

Biology and genetics

Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. Smolewski P et al. Eur J Cancer. 2014 Aug 18. pii: S0959-8049(14)00873-9. doi: 10.1016/j.ejca.2014.07.021. [Epub ahead of print]. Cell membrane associated free kappa light chains are found on a subset of tonsil and in…

Supportive care

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.Iyer SP et al. Br J Haematol. 2014 Aug 19. doi: 10.1111/bjh.13056. [Epub ahead of print].Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis.Frediani…

Complications of myeloma and its treatments

Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. Kosturakis AK et al. J Clin Oncol. 2014 Aug 25. pii: JCO.2013.54.5418. [Epub ahead of print]. Hepatitis B virus reactivation in multiple myeloma patients receiving bortezomib-containing regimens followed by autologous stem cell transplantation. Li J et al. Leuk…

Current treatments

Update of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Mateos MV et al. Blood. 2014 Aug 7. pii: blood-2014-05-573733. [Epub ahead of print]. Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood…